| 中文名称 | 地丹诺辛 |
|---|---|
| 中文别名 | 去羟肌苷;2',3'-双脱氧肌甙;2',3'-双脱氧肌苷;地达诺辛;地丹诺辛;地达诺新;双脱氧肌苷;2,3-二脱氧肌苷;2',3'-二脱氧肌苷;2',3'-Dideoxyinosine 2',3'-二脱氧肌苷;2',3'-二脱氧肌苷(ddI);地达诺辛标准品;地达诺新 EP标准品;地达诺新系统适应性 EP标准品;地丹诺辛 USP标准品;地丹诺辛系统适用性合剂 USP标准品;去羟肌苷标准品;双脱氧胞甙;地达诺辛 双脱氧肌苷;地丹诺辛系统适用性合剂 |
| 英文名称 | Didanosine |
| 英文别名 | Didanosine;2',3'-dideoxyinosine;2,3-Dideoxyinosine;Didansine;2’,3’-Dideoxyinosine;Dideoxyinosine;Dehydroxyinosine Didanosine;ddI;Didanosine SysteM Suitability Mixture;ddIno;9-(2,3-Dideoxy-β-D-ribofuranosyl)hypoxanthine;9-(2,3-Dideoxy-β-D-ribofuranosyl)-6-oxopurine;Videx;Videx EC;Inosine, 2',3'-dideoxy-;Didanosinum;Didanosina;K3GDH6OH08;Didanosinum [INN-Latin];Didanosina [INN-Spanish];9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine;9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one;9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE;BMY;Didanosine and Interferon-.alpha.-2;ddI (Antiviral);HMS2232P22;ddI & sCD4(rsCD4);DDI and rIFN.alpha.2;DIDANOSINE (USP-RS);CCG-220153;J-700356;2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor;MLS001055350;DTXCID402927;AKOS026750545;BP-58651;2',3' Dideoxyinosine;MFCD00077728;DIDANOSINE [EP MONOGRAPH];Didanosine for system suitability, European Pharmacopoeia (EP) Reference Standard;CHEMBL1460;HMS2095O08;T71244;DIDANOSINE [USP MONOGRAPH];D00296;9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine;9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol;SRI-7013-04;NSC612049;Videx(TM);DIDANOSINE [USP IMPURITY];DIDANOSINE [EP IMPURITY];SR-05000001487;HMS2051J11;3'-Azido-3'-deoxythymidine + 2',3'-Dideoxyinosine;Dideoxyinosine (DDI);HMS2089N20;AKOS015901454;Intron A & Videx;NCGC00254496-01;2',3'-Dideoxyinosine (AIDS Initiative);SR-05000001487-2;MLS006011561;(-)-didanosine;Didanosine, United States Pharmacopeia (USP) Reference Standard;Didanosine; 2',3'-dideoxyinosine; 9-(2,3-Dideoxy-beta-d-glycero-pentofuranosyl)-1,9-dihydro-6H-purin-6-one;W-203551;DDI (NUCLEOSIDE);BXZVVICBKDXVGW-NKWVEPMBSA-N;DS-4152 & ddI;Lecithinized superoxide dismutase & Inosine, 2',3'-dideoxy-;DIDANOSINE [MI];DB00900;DIDANOSINE [ORANGE BOOK];Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2;DIDANOSINE [JAN];9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one;CCG-100947;Listera ovata agglutinin & 2',3'-Dideoxyinosine;Hypoxanthine ddN;SMR000058576;HMS3712O08;9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one;Didanosine [USAN:USP:INN:BAN];SMR004703324;DIDANOSINE [INN];HSDB 6548;DIDANOSINE (USP IMPURITY);2DI;Didanosine (USAN:USP:INN:BAN);Tox21_300575;DIDANOSINE [VANDF];Didanosine EC;Didanosine 100 microg/mL in Acetonitrile;NSC 612049;NCGC00159514-03;9-((2R,5S)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-1H-PURIN-6(9H)-ONE;2',3'-Dideoxyinosine & sCD4(soluble recombinant protein);69655-05-6;GTPL4833;ddI & GM-CSF;SRI-7013_07;DIDANOSINE (MART.);Didanosine (JAN/USP/INN);NCGC00259882-01;AC-32186;9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one;NS00000541;HMS3884M06;D3066;NCGC00090691-02;9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran;DIDANOSINUM [WHO-IP LATIN];UNII-K3GDH6OH08;NCGC00164280-01;DIDANOSINE [USP-RS];BRN ... |
| CAS No. | 69655-05-6 |
| 分子式 | C10H12N4O3 |
| 分子量 | 236.23 |
4-(2-((2R,3R)-3-(2,5-二氟苯基)-3-羟基-4-(1H-1,2,4-三唑-1-基)丁-2-基)噻唑-4-基)苯甲腈
N-(丁基磺酰基)-O-[4-(4-哌啶基)丁基]-L-酪氨酸盐酸盐一水合物
2-(4-(1-羟基-4-(4-(羟基二苯基甲基)哌啶-1-基)丁基)苯基)-2-甲基丙酸
7-环戊基-N,N-二甲基-2-((5-(哌嗪-1-基)吡啶-2-基)氨基)-7H-吡咯并[2,3-d]嘧啶-6-甲酰胺
(1-((2R,3R,4S,5R)-3,4-二羟基-5-甲基四氢呋喃-2-基)-5-氟-2-氧代-1,2-二氢嘧啶-4-基)氨基甲酸戊酯
((3S,5R)-5-((1H-1,2,4-三唑-1-基)甲基)-5-(2,4-二氟苯基)四氢呋喃-3-基)甲基 4-甲基苯磺酸酯
N-(3-氯-4-氟苯基)-7-甲氧基-6-(3-吗啉-4-丙氧基)喹唑啉-4-胺
(6R,7R)-3-甲基-7-[(R)-2-氨基-2-苯乙酰氨基]-8-氧-5-硫杂-1-双环[4.2.0]辛-2-烯-2-甲酸
(2R,3S,5S)-3-苄氧基-5-[2-[[(4-甲氧基苯基)二苯基甲基]氨基]-6-苄氧基-9H-嘌呤-9-基]-2-苄氧基甲基环戊醇
(2R,3R,4S,5R)-2-(4-氨基吡咯并[2,1-F][1,2,4]三嗪-7-基)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-甲腈
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。
CopyRight @2025 广东元丰化学试剂有限公司 版权所有 | 隐私政策 条款及条件 | 粤ICP备2025403430号-1
技术支持:库价化学